Marine Drugs (Jun 2024)

Sulfated Polyhydroxysteroid Glycosides from the Sea of Okhotsk Starfish <i>Henricia leviuscula spiculifera</i> and Potential Mechanisms for Their Observed Anti-Cancer Activity against Several Types of Human Cancer Cells

  • Alla A. Kicha,
  • Dmitriy K. Tolkanov,
  • Timofey V. Malyarenko,
  • Olesya S. Malyarenko,
  • Alexandra S. Kuzmich,
  • Anatoly I. Kalinovsky,
  • Roman S. Popov,
  • Valentin A. Stonik,
  • Natalia V. Ivanchina,
  • Pavel S. Dmitrenok

DOI
https://doi.org/10.3390/md22070294
Journal volume & issue
Vol. 22, no. 7
p. 294

Abstract

Read online

Three new monosulfated polyhydroxysteroid glycosides, spiculiferosides A (1), B (2), and C (3), along with new related unsulfated monoglycoside, spiculiferoside D (4), were isolated from an ethanolic extract of the starfish Henricia leviuscula spiculifera collected in the Sea of Okhotsk. Compounds 1–3 contain two carbohydrate moieties, one of which is attached to C-3 of the steroid tetracyclic core, whereas another is located at C-24 of the side chain of aglycon. Two glycosides (2, 3) are biosides, and one glycoside (1), unlike them, includes three monosaccharide residues. Such type triosides are a rare group of polar steroids of sea stars. In addition, the 5-substituted 3-OSO3-α-L-Araf unit was found in steroid glycosides from starfish for the first time. Cell viability analysis showed that 1–3 (at concentrations up to 100 μM) had negligible cytotoxicity against human embryonic kidney HEK293, melanoma SK-MEL-28, breast cancer MDA-MB-231, and colorectal carcinoma HCT 116 cells. These compounds significantly inhibited proliferation and colony formation in HCT 116 cells at non-toxic concentrations, with compound 3 having the greatest effect. Compound 3 exerted anti-proliferative effects on HCT 116 cells through the induction of dose-dependent cell cycle arrest at the G2/M phase, regulation of expression of cell cycle proteins CDK2, CDK4, cyclin D1, p21, and inhibition of phosphorylation of protein kinases c-Raf, MEK1/2, ERK1/2 of the MAPK/ERK1/2 pathway.

Keywords